NCT04916886已完成不适用
To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,021
- 试验地点
- 1
- 主要终点
- GMT of anti SARS-CoV-2 specific neutralizing antibody
研究概览
简要总结
The study is a single-center, randomized and double-blinded trial to evaluate the immunobridging between different manufacture scales, lot-to-lot consistency of the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)(Ad5-nCOV) in population 6-59 years of age. The immunobridging between different manufacture scales will be evaluated first, the immunobridging between different age groups will be evaluated second, the lot-to-lot consistency will be evaluated at last.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 6 Years 至 59 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •6-59 years of age at the time of enrollment;
- •Able to provide consent or obtain consent from guardian to participate in the trial and sign an Informed Consent Form (ICF);
- •Able and willing to complete all the scheduled study procedures during the whole study follow-up period;
- •Axillary temperature ≤37.0℃;
- •IgG ang IgM negative for Covid-19;
- •Have not received any type of Covid-19 vaccines;
- •No contact history of Covid-19; no travel history to medium and high risk regions and abroad in the past 21 days;
- •Participants who are clinically determined to be healthy after checking medical history and physical examination are eligible to receive the product.
排除标准
- •Medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders;
- •History of allergies to any ingredient of Ad5-nCoV, history of serious allergic reactions to any vaccine, history of allergies and immune diseases;
- •Women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period;
- •Acute febrile diseases and infectious diseases, medical history of SARS (SARS-CoV-1);
- •Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg), etc;
- •Severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc;
- •Congenital or acquired angioedema/neurological edema;
- •Urticaria history within 1 year before receiving the study vaccine;
- •Asplenia or functional aspleenia;
- •Thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection);
- •Trypanophobia；
- •History of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis);
- •Prior administration of blood products in last 4 months;
- •Received other investigational drugs within 1 month before the study;
- •Prior administration of live attenuated vaccines within 1 month before the study;
- •Prior administration of subunit or inactivated vaccines within 14 days before the study;
- •Current anti-tuberculosis therapy;
- •Medical history of Covid-19 disease/infection;
- •Any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).
结局指标
主要结局
GMT of anti SARS-CoV-2 specific neutralizing antibody
时间窗: 28 days after vaccination
GMT of anti SARS-CoV-2 specific neutralizing antibody in all groups (wild type variants test).
次要结局
- Stratified analysis on Ad5 vector neutralizing antibody(28 days after vaccination)
- Incidence of Adverse Reactions/Events (AE/AR)(Within 0-28 days after vaccination)
- Incidence of Serious Adverse Events (SAE)(Within 12 months after vaccination)
- GMI of SARS-CoV-2 neutralizing antibody(28 days after vaccination)
- GMT of Ad5 vector neutralizing antibody(28 days after vaccination)
- GMT of SARS-CoV-2 S protein RBD antibody(28 days after vaccination)
- Seroconversion rate of SARS-CoV-2 S protein RBD antibody(28 days after vaccination)
- Seroconversion rate of SARS-CoV-2 neutralizing antibody(28 days after vaccination)
- GMI of Ad5 vector neutralizing antibody(28 days after vaccination)
- GMI of SARS-CoV-2 S protein RBD antibody(28 days after vaccination)
- Incidence of Adverse Events of Special Interest (AESI)(Within 12 months after vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
早期 1 期
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)COVID-19 PandemicCOVID-19 VaccinesNCT05918939Dr. Soetomo General Hospital350
已完成
3 期
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersMeaslesMeningococcal MeningitisMumpsRubellaVaricellaNCT00422292Sanofi Pasteur, a Sanofi Company1,664
已完成
2 期
A Phase 2 Bridging Study to Assess the New Formulation of ETVAXHealty VolunteersPreventable Disease, VaccineNCT05178134Scandinavian Biopharma AB280
进行中（未招募）
3 期
COVID-19 Booster Study in Healthy Adults in AustraliaCOVID-19NCT05658523Murdoch Childrens Research Institute496
招募中
2 期
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy AdultsCOVID-19NCT05258669Ocugen400